Phase II trial of neoadjuvant docetaxel and ZD 1839 (Iressa) [gefitinib] followed by radical prostatectomy in patients with high risk, locally advanced prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2012
At a glance
- Drugs Docetaxel; Gefitinib
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Feb 2012 Actual end date 1 Nov 2007 added as reported by ClinicalTrials.gov.
- 25 Jul 2006 Status change